Effect of sulfonylurea dose escalation on hemoglobin A1c in Veterans Affairs patients with type 2 diabetes

Acta Diabetologica

Volumn 50, Issue 2, 2013, Pages 261-265

  Hurren, Kathryn M ^a   Bartley, Emily P ^b   O'Neill, Jessica L ^b   Ronis, David L ^b,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Dose response; Glipizide; Glyburide; Hemoglobin A1c; Sulfonylurea

Indexed keywords

GLIBENCLAMIDE; GLIPIZIDE; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VETERANS HEALTH; WEIGHT GAIN; WEIGHT REDUCTION;

AGED; CREATININE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIPIZIDE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS;

EID: 84880919649     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-010-0197-1     Document Type: Article

References (22)

1. Micronase (glyburide) package insert (2006) Pfizer Inc., New York, NY
2. Glucotrol (glipizide) package insert (2006) Pfizer Inc., New York, NY
3. Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT (1997) Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM: results of two multicenter, randomized, placebo-controlled clinical trials. Diabetes Care 20(4):597-606
4. Abraira C, Henderson WG, Colwell JA, Nuttall FQ, Comstock JP, Emanuele NV, Levin SR, Sawin CT, Silbert CK (1998) Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes; VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care 21(4):574-579
5. Stenman S, Melander A, Groop PH, Groop LC (1993) What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 118(3):169-172
6. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY (2005) Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 90(1):501-506
7. Takahashi A, Nagashima K, Hamasaki A, Kuwamura N, Kawasaki Y, Ikeda H, Yamada Y, Inagaki N, Seino Y (2007) Sulfonylurea and glinide reduce insulin content, functional expression of KATP channels, and accelerate apoptotic β-cell death in the chronic phase. Diabetes Res Clin Pract 77(3):343-350
8. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA (2006) Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 174(2):169-174
9. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837-853
10. Meinert CL, Knatterud GL, Prout TE, Klimt CR (1970) A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 19:S789-S830
11. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560-2572
12. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 32(1):1-11
13. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH et al (2007) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13(S1):1-68
14. Coppack SW, Lant AF, McIntosh CS, Rodgers AV (1990) Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus. Br J Clin Pharmacol 29:673-684
15. Groop LC, Barzilai N, Ratheiser K, Luzi L, Wahlin-Boll E, Melander A, DeFronzo RA (1991) Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans. Diabetes Care 14(8):724-727
16. Kitabchi AE, Kaminska E, Fisher JN, Sherman A, Pitts K, Bush A, Bryer-Ash M (2000) Comparative efficacy and potency of long-term therapy with glipizide or glyburide in patients with type 2 diabetes mellitus. Am J Med Sci 319(3):143-148
17. Groop L, Groop PH, Stenman S, Saloranta C, Totterman KJ, Fyhrquist F, Melander A (1987) Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment. Diabetes Care 10(6):671-678
18. Birkeland KI, Furuseth K, Melander A, Mowinckel P, Vaaler S (1994) Long-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Diabetes Care 17(1):45-49
19. Kilo C (1988) Multicenter comparison of glyburide and glipizide in the treatment of non-insulin-dependent diabetes mellitus. Clin Ther 10(3):294-303
20. Rosenstock J, Corrao PJ, Goldberg RB, Kilo C (1993) Diabetes control in the elderly: a randomized, comparative study of glyburide versus glipizide in non-insulin-dependent diabetes mellitus. Clin Ther 15(6):1031-1040
21. Kilo C, Meenan A, Bloomgarden Z (1992) Glyburide versus glipizide in the treatment of patients with non-insulin-dependent diabetes mellitus. Clin Ther 14(6):801-812
22. Jaber LA, Wenzloff NJ, Komanicky P, Antal EJ (1990) An evaluation of the therapeutic effects and dosage equivalence of glyburide and glipizide. J Clin Pharmacol 30:181-188